Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke

Completed

Phase 4 Results

Summary of Purpose

This study is randomized, Sodium Ozagrel (Thromboxane A2 Synthase Inhibitor) controlled study on acute ischemic stroke. The primary endpoints were the rate of patients with modified Rankin Scale score of 0-1 at 3 months.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 9 December 2012.

1 Aug 2004 12 Sep 2005 Unavailable 1 Oct 2006 1 Dec 2012 13 Sep 2012
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Conditions

Sponsors

Trial Design

  • Allocation: Randomized
  • Masking: Open Label
  • Purpose: Treatment
  • Endpoint: Efficacy Study
  • Intervention: Parallel Assignment

Contacts

Not available